Home › Survey: Aubagio (Teriflunomide) Trails Gilenya (Fingolimod) for Multiple Sclerosis Treatment
 

Keywords :   


Survey: Aubagio (Teriflunomide) Trails Gilenya (Fingolimod) for Multiple Sclerosis Treatment

2013-06-01 21:06:44| Biotech - Topix.net

BioTrends Research Group, a research and advisory firm located in Exton, Pennsylvania, finds that more than half of surveyed neurologists have prescribed Aubagio - the second oral disease-modifying agent marketed for the treatment of multiple sclerosis - to at least one of their MS patients at 6 months post-launch. While this represents a ... (more)

Tags: multiple treatment survey trails

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Cool Roof Coatings Market to Reach US$9.2B by 2030: Fairfield
26.06LG and Blacknut provide cloud video games through webOS
26.06Universal UK resort to open 365 days a year
26.06Steelwork closures' ripple effect on town's wages
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
More »